Researchers evaluated the chemo-sensitizing potential of the combinatorial regimen of isoliensinine (ISO) and Paclitaxcel on multidrug-resistant-HCT-15 cells to reduce the dose requirement of both ISO and Paclitaxcel.
[Journal Of Biochemical And Molecular Toxicology]